Baxter International Inc. ($BAX) Stock Forecast: Up 5.1% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a global healthcare company specializing in products for various medical conditions. The stock showed strong bullish movement recently.

Why is Baxter International Inc. going up?

BAX stock is up 5.1% on Mar 26, 2026 15:15

• BAX stock rose by 2.39% to $17.12, surpassing its competitors for the third consecutive day.
• The positive market sentiment, reflected in the S&P 500 Index and Dow Jones Industrial Average increases, likely contributed to this rise.
• Investor optimism about Baxter's product portfolio and growth opportunities, especially in healthcare, may have fuelled its strong performance.
• Although therapy animal program news is beneficial for healthcare, it had minimal direct impact on BAX's stock movement.

BAX Price Chart

BAX Technical Analysis

BAX News

Assessing Axogen (AXGN) Valuation After Growth Outlook And FDA Approval Fuel Strong One Year Share Price Gain

Axogen (AXGN) has seen significant share price appreciation over the past year, driven by expectations of 20% revenue growth in 2025, expanded reimbursement, FDA approval of a key nerve repair product, and anticipated positive free cash flow in 2026. While analysts see the stock as undervalued with a fair value of $40.56, its current P/S ratio of 7.5x is higher than the industry average, suggesting potential valuation risk if sentiment shifts. Investors are encouraged to review the company's financial data to form their own conclusions on its future prospects.

https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/assessing-axogen-axgn-valuation-after-growth-outlook-and-fda

Baxter International Inc. stock outperforms competitors on strong trading day

Shares of Baxter International Inc. (BAX) rose 2.39% to $17.12 on Wednesday, outperforming the broader market. This marked the stock's third consecutive day of gains, occurring during a strong trading session where the S&P 500 Index and Dow Jones Industrial Average also saw increases.

https://www.marketwatch.com/data-news/baxter-international-inc-stock-outperforms-competitors-on-strong-trading-day-b5819f62-ead20f1a8172?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqctJib65hc0sLrLgwEkbvpxLk5g8tFtowqINarWfKHCHRsr7LaSOg6S&gaa_ts=69c49145&gaa_sig=mnHo26uEvQeLCwM5U-yBh0uWmToJtFfQqH2fFykYbjK4jLy3OKkWUABRAXZtPMyKcMsm1CtXIW0fjU-XPhfHLA%3D%3D

10 Best Mid Cap Value Stocks to Buy in 2026

This article, part of a larger list, focuses on Revvity, Inc. (NYSE:RVTY) as one of the best mid-cap value stocks to buy in 2026. Stifel maintained a Hold rating on the company with a $110 price target, following management's cautious yet optimistic outlook for 2026, driven by steady-state pharma/biotech growth and positive indicators despite some short-term headwinds like weak academic demand and China's market. Revvity offers advanced health science solutions across various segments.

https://www.insidermonkey.com/blog/10-best-mid-cap-value-stocks-to-buy-in-2026hold-1724231/2/

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

Pet Partners and the Baxter Foundation announced a new partnership to expand therapy animal programs in healthcare settings, aiming to reach 100,000 patients and healthcare professionals over a two-year pilot in Northern California, Upstate New York, and Greater Chicago, IL. This collaboration, inspired by a patient's healing bond with a dog named Baxter, seeks to strengthen healthcare resilience by providing resources, training, and infrastructure for animal-assisted interventions. The initiative also includes supporting volunteer education, advancing safety protocols, conducting research on the impact of therapy animals on healthcare workers, and engaging Baxter employees in volunteering efforts.

https://www.prnewswire.com/news-releases/pet-partners-and-the-baxter-foundation-expand-therapy-animal-programs-to-support-100-000-patients-and-healthcare-workers-in-two-year-pilot-302724420.html

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

Pet Partners and the Baxter Foundation have partnered to launch a two-year pilot program expanding therapy animal access in healthcare settings. This initiative aims to reach 100,000 patients and healthcare workers in regions like Northern California, Upstate New York, and Greater Chicago, IL. The partnership will focus on increasing therapy animal visits, enhancing volunteer training, and conducting research on the impact of therapy animals to strengthen healthcare resilience and provide comfort.

https://www.marketscreener.com/news/pet-partners-and-the-baxter-foundation-expand-therapy-animal-programs-to-support-100-000-patients-an-ce7e5ed3da81f327

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.1% Today

QTUM ($QTUM) Crypto Forecast: Down 6.0% Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

Acuity Brands Inc. ($AYI) Stock Forecast: Down 5.2% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.3% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 7.6% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 8.6% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.3% Today

Intel Corporation ($INTC) Stock Forecast: Down 6.4% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

Baxter International Inc. Price History

13.01.2026 - BAX Stock was up 5.2%

• Q4 2025 earnings call transcript revealed detailed discussions on financial performance and future outlook, suggesting positive prospects that resonated well with investors.
• Despite a net loss reported in the 2025 10-K report, Baxter's focus on streamlining operations through divestitures and core segments may have boosted investor confidence in the company's long-term strategy.
• A downgrade to a hold rating following weak Q4 results and a disappointing FY 2026 guide could have initially affected investor sentiment. However, the subsequent appointment of Michael R. McDonnell to the Board of Directors and strategic efforts for a turnaround likely instilled optimism, leading to the stock's bullish movement today.

19.02.2026 - BAX Stock was down 5.7%

• Baxter International (BAX) recently saw a decline in its stock price following the departure of its CFO, Joel Grade, amid ongoing governance reviews and product safety investigations.
• Concerns over the CFO transition and governance matters have led to uncertainties about the company's financial strategy and cost management in the eyes of investors.
• The questioning of Axogen's (AXGN) valuation and the growth of the regenerative medicine sector could have also played a part in affecting investor confidence in Baxter International, contributing to the downward trend.
• It is recommended for investors to observe how Baxter International communicates its financial strategies and handles risks during these changes to evaluate the potential impact on its stock performance.

03.02.2026 - BAX Stock was down 5.2%

• A reduction in stake by CI Investments Inc. in BlackRock might have prompted investors to reallocate their funds, affecting the market sentiment.
• Smith+Nephew's innovative technologies displayed at the AAOS Annual Meeting could have diverted investor attention away from Baxter International, resulting in decreased demand for BAX shares.
• An expansion by Intuitive in Europe may have shifted focus in the overall healthcare market, especially in the medical devices and biotechnology sectors, potentially diverting interest from Baxter International.
• The projected growth in the hemodialysis therapy market suggests a potential change in investor preferences towards companies in the renal care sector, potentially overshadowing Baxter International's performance for the day.

04.01.2026 - BAX Stock was up 5.2%

• BAX encountered challenges in Q4, such as disappointing Q3 results, a dividend reduction, and delays in IV fluid volume normalization and Novum pump shipments, resulting in underperformance.
• Growth projections in the outpatient oncology infusion market could have a beneficial impact on BAX, given its role in fostering innovation in this area.
• Hospitals opting to phase out desflurane over environmental concerns could indirectly assist BAX, as the transition to eco-friendly alternatives may boost the company's image.
• The announcement of Avidity Biosciences' share distribution and Axogen's recent equity offerings might have positively influenced investor sentiment, contributing to the bullish momentum in BAX's stock.

12.01.2026 - BAX Stock was down 12.7%

• Baxter International Inc. reported a Q4 earnings miss and provided a weak outlook for 2026, leading to a sharp decline in its stock price.
• Despite revenue exceeding estimates, the company's adjusted EPS fell short, and its projected earnings for the upcoming year were below expectations, causing concern among investors.
• The substantial GAAP loss and cautious guidance for 2026 highlighted potential profitability and operational challenges for the company, contributing to the bearish market movement.
• The stock tumbled as much as 14.63% in pre-market trading following the disappointing financial results and outlook, reflecting investors' apprehensions about Baxter's performance in the near future.

12.01.2026 - BAX Stock was down 15.0%

• Baxter International Inc. (BAX) saw its stock price plummet by 13.3% to 14.63% in pre-market trading following the earnings announcement.
• The decline in BAX's stock price can be linked to the fourth-quarter earnings falling below analyst expectations, notably with an adjusted EPS of $0.44 missing projections.
• Furthermore, the company's conservative 2026 forecast, with anticipated flat to 1% sales growth and adjusted EPS below consensus estimates, added to investor worries about Baxter's future.
• Despite introducing a new operating model aimed at streamlining its operations and enhancing performance, Baxter's stock experienced a significant drop, overshadowing the efforts to mitigate the impact of the disappointing earnings and outlook.

18.01.2026 - BAX Stock was up 7.5%

• Baxter International (BAX) has experienced a strong bullish movement, with its stock rising by 4.80%.
• The positive market reaction could be attributed to investors potentially viewing the recent losses and challenges as temporary setbacks, leading to increased confidence in the company's future prospects.
• Despite concerns about earnings volatility and debt, the market seems to be responding positively to Baxter International's recent performance, outperforming its competitors on a strong trading day.
• The bullish movement might also be influenced by the overall positive sentiment in the market, as indicated by modest gains in the S&P 500 and Dow Jones Industrial Average.

18.01.2026 - BAX Stock was up 6.6%

• Baxter International (BAX) saw a strong bullish movement despite financial challenges and negative sentiment from analysts.
• The positive market movement could be attributed to investors potentially viewing the company's low valuation metrics, such as the P/S ratio, as compensatory for concerns about earnings volatility and high debt levels.
• The market might be reacting favorably to Baxter International's resilience in the face of financial hurdles, possibly seeing potential for a turnaround in its earnings recovery narrative.
• Despite the obstacles pointed out by analysts, the bullish trend in Baxter International's stock price suggests that investors are optimistic about the company's future prospects and its ability to navigate through the current challenges.

17.02.2026 - BAX Stock was up 5.3%

• Baxter International's stock experienced a strong bullish movement today, despite recent challenges and uncertainties surrounding the departure of CFO Joel Grade.
• The appointment of Anita Zielinski as the interim CFO may have instilled confidence in investors, signaling continuity and stability in the company's financial leadership.
• Despite hitting a 52-week low recently, the market reacted positively to the company's reiteration of its full-year 2026 financial outlook, potentially indicating optimism about Baxter's future performance.
• The divestment of shares by California Public Employees Retirement System in ON Semiconductor Corporation (not directly related to Baxter) may have indirectly impacted market sentiment, leading investors to shift focus towards Baxter International instead.

15.00.2026 - BAX Stock was up 5.2%

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

26.02.2026 - BAX Stock was up 5.1%

• BAX stock rose by 2.39% to $17.12, surpassing its competitors for the third consecutive day.
• The positive market sentiment, reflected in the S&P 500 Index and Dow Jones Industrial Average increases, likely contributed to this rise.
• Investor optimism about Baxter's product portfolio and growth opportunities, especially in healthcare, may have fuelled its strong performance.
• Although therapy animal program news is beneficial for healthcare, it had minimal direct impact on BAX's stock movement.

10.01.2026 - BAX Stock was up 5.3%

• The bullish movement in Baxter International Inc. (BAX) could be attributed to the positive news surrounding the company's commitment to respiratory health for patients, showcasing its dedication to improving patient care and quality of life.
• The downgrades from financial firms may have initially caused some uncertainty in the market, but the strong focus on innovative healthcare solutions and patient support likely reassured investors, leading to the bullish trend.
• The workforce reduction at a plant impacted by Hurricane Helene could have been perceived as a strategic move by Baxter to streamline operations and enhance efficiency, potentially positively impacting the company's bottom line and investor confidence.
• The overall positive sentiment towards Baxter International Inc. (BAX) amid its focus on healthcare innovation and patient support likely contributed to the bullish market movement despite some external challenges and analyst downgrades.